›› 2019, Vol. 4 ›› Issue (8): 39-42.
Previous Articles Next Articles
Zhang Jianyi1, Zhang Jing2, Wang Jianhua2, Duan Saizhu2, Zhang Rongsheng2*
Received:
Revised:
Online:
Published:
Abstract:
Objective: To retrospectively analyze the efficacy and safety of apatinib combined with radiochemotherapy in the treatment of advanced colorectal cancer. Methods: The efficacy and safety of two patients with advanced colorectal cancer treated with apatinib combined with radiochemotherapy were analyzed and related literatures were reviewed. Results: Two patients were followed up for 12 months, all of whom had achieved stable disease and benefited from overall survival. The main adverse reactions were fatigue, oral pain, and were tolerable after treatment or dose adjustment. Conclusion: The efficacy of apatinib combined with radiochemotherapy in the treatment of advanced colorectal cancer is positive, and adverse reactions can be tolerated.
Key words: advanced colorectal cancer, apatinib, combination therapy, curative effect analysis
CLC Number:
R735.3
ZHANG Jian-Yi, ZHANG Jing, WANG Jian-Hua, DUAN Sai-Zhu, ZHANG Rong-Sheng. Apatinib Combined with Radiochemotherapy for Advanced Colorectal Cancer in 2 Cases and Literature Review[J]. , 2019, 4(8): 39-42.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/
http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/Y2019/V4/I8/39
〔1〕CHEN W，SUN K，ZHENG R，et al. Cancer incidence and mortality in China，2014〔J〕. Chin J Cancer Res，2018，30 （1）：1-12. 〔2〕秦叔逵，李进. 阿帕替尼治疗胃癌的临床应用专家共 识〔J〕. 临床肿瘤学杂志，2015，20（9）：841-847. 〔3〕LI J，ZHAO X，CHEN L，et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor recep? tor-2 inhibitor YN968D1 in patients with advanced malig? nancies〔J〕. BMC Cancer，2010，10：529. 〔4〕LI J，QIN S，XU J，et al. Apatinib for Chemotherapy-Refrac? tory Advanced Metastatic Gastric Cancer：Results From a Randomized，Placebo-Controlled，Parallel-Arm，Phase Ⅱ Trial〔J〕. J Clin Oncol，2013，31（26）：3219-3225.
〔5〕LI J，QIN S，XU J，et al. Randomized，Double-Blind，Placebo- Controlled Phase Ⅲ Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adeno? carcinoma of the Stomach or Gastroesophageal Junction〔J〕. J Clin Oncol，2016，34（13）：1448-1454. 〔6〕HU X，CAO J，HU W，et al. Multicenter phase Ⅱ study of Apatinib in non- triple- negative metastatic breast can? cer〔J〕. BMC Cancer，2014，14：820. 〔7〕HU X，ZHANG J，XU B ，et al. Multicenter phase Ⅱ study of apatinib，a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer〔J〕. Int J Cancer，2014，135（8）：1961-1969. 〔8〕涂艳，彭枫. 阿帕替尼治疗恶性肿瘤的临床研究进展〔J〕. 中国肿瘤临床，2016，43（12）：545-548. 〔9〕孙培培，张龙，张泰，等. 单药阿帕替尼治疗二线及二线 以上化疗失败的晚期大肠癌患者疗效分析〔J〕. 临床肿 瘤学杂志，2017，22（7）：646-649. 〔10〕麻国新，甄书漫. 阿帕替尼治疗直肠癌术后放化疗后肺 转移1例〔J〕. 中国肿瘤临床，2016，43（23）：1068. 〔11〕彭雨，李海涛，杨文丽，等. 阿帕替尼在既往二线及二线以 上治疗失败后的晚期肝细胞癌中的临床疗效分析〔J〕. 徐州医学院学报，2017，37（3）：178-181.
